David Gindler

David Gindler specializes in complex commercial litigation, with an emphasis on patent, trade secret, and related intellectual property disputes. His work spans a broad array of industries and technologies, ranging from biotechnology, medical devices, computer architecture, microprocessor design, advanced semiconductor materials, financial services, and business methods. Mr. Gindler has represented both established and emerging commercial and non-profit organizations, including CooperVision, PDL BioPharma, Ariosa Diagnostics, Alnylam Pharmaceuticals, INOVA Diagnostics, Inc., Aon Corporation, NCR Corporation, Polycom, Columbia University, Massachusetts Institute of Technology, Arizona State University, and City of Hope. Mr. Gindler was one of the principal trial attorneys in City of Hope National Medical Center v. Genentech, Inc., in which Irell & Manella obtained a $302 million compensatory damages award arising from Genentech’s failure to pay royalties owed on patents relating to fundamental technology that helped to create the biotechnology industry. The $302 million compensatory damages award was upheld by both the California Court of Appeal and the California Supreme Court, and is the largest jury verdict ever affirmed in a published California appellate decision. Mr. Gindler is also highly regarded for representing technology, entertainment, and multimedia companies and leading financial institutions in hotly contested matters concerning the protection of trade secrets and related rights. He frequently litigates cases requiring prompt injunctive relief to prevent misappropriation of trade secrets and proprietary information, as well as cases involving allegations of employee raiding and unfair competition. He has handled matters on behalf of a diverse group of clients, including MTV Networks, Paramount Pictures, Merrill Lynch, and Credit Suisse First Boston. UCLA School of Law (J.D., 1984) Pomona College (B.A., Philosophy and Economics, 1981)